Episode
Vaccine willingness and mandates
We explore the debate surrounding vaccines, vaccine mandates, and the willingness to obtain a vaccine - analyzing the argument in ...
Overcoming outcomes bias in healthcare
Healthcare is defined by data. But data is nothing more than an outcome, susceptible to outcomes bias. We explore this ...
Creating change in healthcare – courts or politics
We discuss how change works in healthcare, and whether it makes sense to approach the courts or to pursue political ...
Mens rea in Healthcare
Complexity, healthcare, and healthcare law - three seemingly disparate concepts tied together by the complexity that defines each one of ...
Systematizing Medical Input into Legal Cases
We explore how physicians and physician organizations can become more active in healthcare legal cases.
Healthcare’s Constitutional Crisis
Healthcare is growing ever more complex, and in this complexity, the laws, being restrictive in nature, produce inequitable distributions of ...
Imagination in Healthcare
Is imagination important in healthcare? If so, how and where can it be used?
Substitutions Passing As Solutions
In healthcare, many politicians and law enforcement agents substitute complex healthcare policy questions for more simplified questions and seek to ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more